Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T21:12:34.098Z.
Calculation as of: 2026-10-06T21:12:34.098Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e0aae41c25609cbe98cd8c59fbdc20e812e1ea61d6a67e0b8df2c56749153647
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Kyverna Therapeutics, Inc.
Market Cap
$374.50M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$376.01M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$376.19M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$369.50M
Operating Cash Flow Yield
N/A
TTM Avg
14.06%
3Y Avg
11.48%
5Y Avg
11.48%
Market Cap
$380.37M
Operating Cash Flow Yield
4.48%
TTM Avg
6.07%
3Y Avg
5.74%
5Y Avg
4.65%
Market Cap
$385.15M
Operating Cash Flow Yield
N/A
TTM Avg
16.47%
3Y Avg
16.47%
5Y Avg
9.15%
Market Cap
$361.64M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$359.53M
Operating Cash Flow Yield
N/A
TTM Avg
15.24%
3Y Avg
15.24%
5Y Avg
15.24%
Market Cap
$355.43M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $374.50M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.01M | N/A | N/A | N/A | N/A |
| Zura Bio Limited (ZURA)vs › | $376.19M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $369.50M | N/A | 14.06% | 11.48% | 11.48% |
| Orthofix Medical Inc. (OFIX)vs › | $380.37M | 4.48% | 6.07% | 5.74% | 4.65% |
| REGENXBIO Inc. (RGNX)vs › | $385.15M | N/A | 16.47% | 16.47% | 9.15% |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 15.24% | 15.24% | 15.24% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 17.10% | 15.02% | 13.56% | 11.99% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
